NasdaqGM - Delayed Quote USD

Theravance Biopharma, Inc. (TBPH)

9.12 -0.02 (-0.22%)
At close: April 26 at 4:00 PM EDT
8.88 -0.24 (-2.63%)
After hours: April 26 at 4:05 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Rick E. Winningham M.B.A. Chairman & CEO 1.3M -- 1960
Mr. Aziz Sawaf C.F.A. Senior VP & CFO 583.5k -- 1982
Mr. Stuart Knight VP of IT&I and Chief Information Officer -- -- --
Ms. Gail B. Cohen Vice President of Corporate Communications & Investor Relations -- -- --
Mr. Brett A. Grimaud Esq. Senior VP, General Counsel & Secretary -- -- 1974
Ms. Rhonda F. Farnum Chief Business Officer and Senior VP of Commercial & Medical Affairs 942.81k -- 1965
Ms. Stacy L. Pryce Senior VP & Chief Strategy Officer -- -- --
Dr. Aine Miller Ph.D. SVP of Dev., VP of Regu., Quality, Clinical Safety & Pharmacovigilance and Head of Ireland Office -- -- --

Theravance Biopharma, Inc.

901 Gateway Boulevard
South San Francisco, CA 94080
United States
650 808 6000 https://www.theravance.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
99

Description

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Corporate Governance

Theravance Biopharma, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 3; Board: 5; Shareholder Rights: 6; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 06, 2024 - May 10, 2024
Theravance Biopharma, Inc. Earnings Call

Related Tickers

SYBX Synlogic, Inc.
1.8700
-1.06%
 
PMVP PMV Pharmaceuticals, Inc.
1.7500
+2.34%
 
PRTC PureTech Health plc
28.50
+2.24%
 
KALV KalVista Pharmaceuticals, Inc.
10.78
+2.76%
 
CTMX CytomX Therapeutics, Inc.
1.5900
-0.62%
 
SPRO Spero Therapeutics, Inc.
1.4600
+2.10%
 
LVTX LAVA Therapeutics N.V.
2.7300
+3.41%
 
ZA8.BE Zymeworks Inc
7.70
+1.32%
 
RPHM Reneo Pharmaceuticals, Inc.
1.6700
+1.21%
 
XNCR Xencor, Inc.
19.98
+3.90%